Cytology Assessment Can Predict Survival for Patients With Metastatic Pancreatic Neuroendocrine Neoplasms

被引:11
|
作者
Sigel, Carlie S. [1 ]
Guo, Huimin [1 ]
Sigel, Keith M. [2 ]
Zhang, Ming [1 ]
Rekhtman, Natasha [1 ]
Lin, Oscar [1 ]
Klimstra, David S. [1 ]
Jungbluth, Achim A. [1 ]
Tang, Laura K. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA
[2] Icahn Sch Med Mt Sinai, Div Gen Internal Med, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
cytology; grade; differentiation; Ki-67; index; metastatic; neuroendocrine carcinoma; pancreas; pancreatic neuroendocrine tumor; HIGH-GRADE; LABELING INDEX; TUMORS; CARCINOMAS; DISTINCT; CELL;
D O I
10.1002/cncy.21817
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Histological features and Ki-67 index have known usefulness in predicting prognosis and guiding therapy among patients with metastatic pancreatic neuroendocrine neoplasms. Fine-needle aspiration may offer advantages for Ki-67 assessment because the technique obtains highly cellular, well-preserved specimens with the potential for broader tumor sampling. In the current study, the authors evaluated concordance for grade and differentiation between concurrent core needle biopsy and cytology preparations. Cytological features and grade then were correlated with survival. METHODS: Differentiation, grade by Ki-67 index, and correlation of these features with survival were compared between concurrent core needle biopsy and cytology specimens from 44 patients with metastatic pancreatic neuroendocrine neoplasms. RESULTS: Differentiation by cytology smear resulted in 38 cases of well (86%) and 6 cases of poor (14%) differentiation. Agreement for differentiation between smear and cell block, smear and core needle biopsy, and cell block and core needle biopsy was 88%, 94%, and 83%, respectively, and agreement for grade was 68%, 54%, and 22%, respectively. Cytology differentiation and cytology grade were found to be strong predictors of outcome with respective hazard ratios of 8.3 (95% confidence interval [95% CI], 3.1-22.1; P<.001) and 1.9 (95% CI, 1.2-2.9) for each ascending grade. The median disease-specific survival cytology projections were 121 months (95% CI, 57-185 months [estimated]) for grade 1, 45 months (95% CI, 29-87 months) for grade 2, and 19 months (95% CI, 1-44 months) for grade 3, with median survivals of 45 months and 3 months, respectively, for patients with well-differentiated and poorly differentiated neuroendocrine tumors (P<. 001). CONCLUSIONS: Grading of pancreatic neuroendocrine neoplasms on cytology may not correlate exactly with concurrent core needle biopsy, but cytology differentiation and grade are predictive of survival based on stage-adjusted analysis. (C) 2017 American Cancer Society.
引用
收藏
页码:188 / 196
页数:9
相关论文
共 50 条
  • [41] Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
    Kurita, Yusuke
    Kobayashi, Noritoshi
    Hara, Kazuo
    Mizuno, Nobumasa
    Kuwahara, Takamichi
    Okuno, Nozomi
    Haba, Shin
    Tokuhisa, Motohiko
    Hasegawa, Sho
    Sato, Takamitsu
    Hosono, Kunihiro
    Kato, Shingo
    Kessoku, Takaomi
    Endo, Itaru
    Shimizu, Yasuhiro
    Kubota, Kensuke
    Nakajima, Atsushi
    Ichikawa, Yasushi
    Niwa, Yasumasa
    INTERNAL MEDICINE, 2023, 62 (02) : 159 - 167
  • [42] Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms
    Lee, Lingaku
    Ito, Tetsuhide
    Igarashi, Hisato
    Ueda, Keijiro
    Fujiyama, Takashi
    Kawabe, Ken
    Ogawa, Yoshihiro
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2017, 24 (02) : 95 - 102
  • [43] Alternative Lengthening of Telomeres Predicts Metastatic Disease and Poor Survival in Patients With Pancreatic Neuroendocrine Tumors
    Kinowaki, Y.
    Matsuda, Y.
    Fukumura, Y.
    Kudo, A.
    Akashi, T.
    Kitagawa, M.
    PANCREAS, 2019, 48 (10) : 1462 - 1462
  • [44] Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms
    Zhang, Pin
    Xiao, Zhiwen
    Xu, Huaxiang
    Zhu, Xinzhe
    Wang, Lei
    Huang, Dan
    Liang, Yun
    Ni, Quanxing
    Chen, Jie
    Yu, Xianjun
    Luo, Guopei
    ENDOCRINE, 2022, 77 (02) : 262 - 271
  • [45] Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms
    Hiroaki Ono
    Atsushi Kudo
    Keiichi Akahoshi
    Toshiro Ogura
    Kosuke Ogawa
    Daisuke Ban
    Shinji Tanaka
    Minoru Tanabe
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 793 - 799
  • [46] Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms
    Ono, Hiroaki
    Kudo, Atsushi
    Akahoshi, Keiichi
    Ogura, Toshiro
    Ogawa, Kosuke
    Ban, Daisuke
    Tanaka, Shinji
    Tanabe, Minoru
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (03) : 793 - 799
  • [47] Surgery for pancreatic neuroendocrine neoplasms in patients with age ≥ 75 years
    Milanetto, A. C.
    Gabriel, G.
    Fassan, M.
    Pasquali, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 254 - 254
  • [48] Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms
    Pin Zhang
    Zhiwen Xiao
    Huaxiang Xu
    Xinzhe Zhu
    Lei Wang
    Dan Huang
    Yun Liang
    Quanxing Ni
    Jie Chen
    Xianjun Yu
    Guopei Luo
    Endocrine, 2022, 77 : 262 - 271
  • [49] Radiological embolization of liver metastases in patients with pancreatic neuroendocrine neoplasms
    Milanetto, A. C.
    David, A.
    Ponzoni, A.
    Pasquali, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 165 - 165
  • [50] Development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms
    Liao, Tianbao
    Su, Tingting
    Huang, Lina
    Li, Bixun
    Feng, Lu-Huai
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (01) : 85 - 90